文献速递乳腺癌

瑞博西利联合来曲唑对比化疗治疗绝经后激素受体阳性HER2阴性luminal B型乳腺癌:CORALLEEN开放标签多中心随机2期试验

Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2019-12-11

CORALLEEN试验在西班牙21家医院纳入106例绝经后激素受体阳性、HER2阴性、PAM50 luminal B型早期乳腺癌患者,随机接受瑞博西利联合来曲唑或蒽环序贯紫杉类化疗。

要点

  • 瑞博西利联合来曲唑组最常见3-4级不良事件为中性粒细胞减少(43%)和ALT升高(20%)
  • 化疗组最常见3-4级不良事件为中性粒细胞减少(60%)和发热性中性粒细胞减少(13%)

核心结论

  • 部分高危早期激素受体阳性HER2阴性乳腺癌患者经CDK4/6抑制剂联合内分泌治疗可实现分子降期。

研究设计与样本

  • CORALLEEN为平行组、多中心、随机、开放标签、2期试验,在西班牙21家医院完成。
  • 纳入106例绝经后(≥18岁)I-IIIA期激素受体阳性、ECOG 0-1、HER2阴性、PAM50 luminal B型、MRI可测量原发肿瘤≥2 cm的可手术乳腺癌患者。
  • 随机按肿瘤大小和淋巴结受累分层;主要终点为改良意向治疗人群中手术时PAM50低复发风险(ROR)疾病的比例。

主要发现

  • 2017年7月27日至2018年12月7日共入组106例患者;基线时92例(87%)为高ROR疾病,14例(13%)为中ROR疾病。
  • 瑞博西利联合来曲唑组最常见3-4级不良事件为中性粒细胞减少(51例中22例,43%)和丙氨酸氨基转移酶升高(51例中10例,20%)。
  • 化疗组最常见3-4级不良事件为中性粒细胞减少(52例中31例,60%)和发热性中性粒细胞减少(52例中7例,13%);两组均未观察到死亡。

临床怎么用

  • 对于高危早期激素受体阳性HER2阴性luminal B型乳腺癌,瑞博西利联合来曲唑可作为新辅助化疗的潜在替代方案之一,但需结合分子降期结果个体化选择。

局限性

  • 本研究为2期试验,样本量有限,主要终点为分子指标而非长期生存结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In hormone receptor-positive, HER2-negative early stage breast cancer, cyclin-dependent kinases 4 and 6 (CDK4/6) inhibition in combination with endocrine therapy could represent an alternative to multiagent chemotherapy. We aimed to evaluate the biological and clinical activity of neoadjuvant ribociclib plus letrozole in the luminal B subtype of early stage breast cancer. METHODS: CORALLEEN is a parallel-arm, multicentre, randomised, open-label, phase 2 trial completed across 21 hospitals in Spain. We recruited postmenopausal women (≥18 years) with stage I-IIIA hormone receptor-positive, Eastern Cooperative Oncology Group Performance Status 0-1, HER2-negative breast cancer and luminal B by PAM50 with histologically confirmed, operable primary tumour size of at least 2 cm in diameter as measured by MRI. Patients were randomly assigned (1:1) using a web-based system and permuted blocks of 25 to receive either six 28-days cycles of ribociclib (oral 600 mg once daily for 3 weeks on, 1 week off) plus daily letrozole (oral 2·5 mg/day) or four cycles of doxorubicin (intravenous 60 mg/m2) and cyclophosphamide (intravenous 600 mg/m2) every 21 days followed by weekly paclitaxel (intravenous 80 mg/m2) for 12 weeks. The total duration of the neoadjuvant therapy was 24 weeks. Randomisation was stratified by tumour size and nodal involvement. Samples were prospectively collected at baseline (day 0), day 15, and surgery. The primary endpoint was to evaluate the proportion of patients with PAM50 low-risk-of-relapse (ROR) disease at surgery in the modified intention-to-treat population including all randomly assigned patients who received study drug and had a baseline and at least one post-baseline measurement of ROR score. The PAM50 ROR risk class integrated gene expression data, tumour size, and nodal status to define prognosis. This trial was registered at ClinicalTrials.gov, NCT03248427. FINDINGS: Between July 27, 2017 to Dec 7, 2018, 106 patients were enrolled. At baseline, of the 106 patients, 92 (87%) patients had high ROR disease (44 [85%] of 52 in the ribociclib and letrozole group and 48 [89%] of 54 in the chemotherapy group) and 14 (13%) patients had intermediate-ROR disease (eight [15%] and six [11%]). Median follow-up was 200·0 days (IQR 191·2-206·0). At surgery, 23 (46·9%; 95% CI 32·5-61·7) of 49 patients in the ribociclib plus letrozole group and 24 (46·1%; 32·9-61·5) of 52 patients in the chemotherapy group were low-ROR. The most common grade 3-4 adverse events in the ribociclib plus letrozole group were neutropenia (22 [43%] of 51 patients) and elevated alanine aminotransferase concentrations (ten [20%]). The most common grade 3-4 adverse events in the chemotherapy group were neutropenia (31 [60%] of 52 patients) and febrile neutropenia (seven [13%]). No deaths were observed during the study in either group. INTERPRETATION: Our results suggest that some patients with high-risk, early stage, hormone receptor-positive, HER2-negative breast cancer could achieve molecular downstaging of their disease with CDK4/6 inhibitor and endocrine therapy. FUNDING: Novartis, Nanostring, Breast Cancer Research Foundation-AACR Career Development Award.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Prat A, Saura C, Pascual T, et al. Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2019. PMID: 31838010. doi:10.1016/S1470-2045(19)30786-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。